Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance.
Zandi Z, Kashani B, Alishahi Z, Pourbagheri-Sigaroodi A, Esmaeili F, Ghaffari SH, Bashash D, Momeny M. Zandi Z, et al. Among authors: kashani b. J Cancer Res Clin Oncol. 2022 Jan;148(1):57-70. doi: 10.1007/s00432-021-03874-2. Epub 2022 Jan 4. J Cancer Res Clin Oncol. 2022. PMID: 34981193 Review.
TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.
Zandi Z, Kashani B, Poursani EM, Bashash D, Kabuli M, Momeny M, Mousavi-Pak SH, Sheikhsaran F, Alimoghaddam K, Mousavi SA, Ghaffari SH. Zandi Z, et al. Among authors: kashani b. Eur J Pharmacol. 2019 Jun 15;853:256-263. doi: 10.1016/j.ejphar.2019.03.046. Epub 2019 Mar 28. Eur J Pharmacol. 2019. PMID: 30930249
Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Momeny M, Sankanian G, Hamzehlou S, Yousefi H, Esmaeili F, Alishahi Z, Karimi B, Zandi Z, Shamsaiegahkani S, Sabourinejad Z, Kashani B, Nasrollahzadeh A, Mousavipak SH, Mousavi SA, Ghaffari SH. Momeny M, et al. Among authors: kashani b. Eur J Pharmacol. 2020 Sep 5;882:173298. doi: 10.1016/j.ejphar.2020.173298. Epub 2020 Jun 25. Eur J Pharmacol. 2020. PMID: 32593665
Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation.
Baakhlagh S, Kashani B, Zandi Z, Bashash D, Moradkhani M, Nasrollahzadeh A, Yaghmaei M, Mousavi SA, Ghaffari SH. Baakhlagh S, et al. Among authors: kashani b. Int Immunopharmacol. 2021 Jan;90:107202. doi: 10.1016/j.intimp.2020.107202. Epub 2020 Dec 2. Int Immunopharmacol. 2021. PMID: 33278749
46 results